Literature DB >> 33573263

Equilibrative Nucleoside Transporters Mediate the Import of Nicotinamide Riboside and Nicotinic Acid Riboside into Human Cells.

Andrey Kropotov1, Veronika Kulikova1,2, Kirill Nerinovski3, Alexander Yakimov4, Maria Svetlova1, Ljudmila Solovjeva1, Julia Sudnitsyna2, Marie E Migaud5, Mikhail Khodorkovskiy1,4, Mathias Ziegler6, Andrey Nikiforov1.   

Abstract

Nicotinamide riboside (NR), a new form of vitamin B3, is an effective precursor of nicotinamide adenine dinucleotide (NAD+) in human and animal cells. The introduction of NR into the body effectively increases the level of intracellular NAD+ and thereby restores physiological functions that are weakened or lost in experimental models of aging and various pathologies. Despite the active use of NR in applied biomedicine, the mechanism of its transport into mammalian cells is currently not understood. In this study, we used overexpression of proteins in HEK293 cells, and metabolite detection by NMR, to show that extracellular NR can be imported into cells by members of the equilibrative nucleoside transporter (ENT) family ENT1, ENT2, and ENT4. After being imported into cells, NR is readily metabolized resulting in Nam generation. Moreover, the same ENT-dependent mechanism can be used to import the deamidated form of NR, nicotinic acid riboside (NAR). However, NAR uptake into HEK293 cells required the stimulation of its active utilization in the cytosol such as phosphorylation by NR kinase. On the other hand, we did not detect any NR uptake mediated by the concentrative nucleoside transporters (CNT) CNT1, CNT2, or CNT3, while overexpression of CNT3, but not CNT1 or CNT2, moderately stimulated NAR utilization by HEK293 cells.

Entities:  

Keywords:  NAD+ metabolism; concentrative nucleoside transporters; equilibrative nucleoside transporters; human cells; nicotinamide riboside; nicotinic acid riboside

Year:  2021        PMID: 33573263      PMCID: PMC7866510          DOI: 10.3390/ijms22031391

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  10 in total

Review 1.  Regulation of NAD+ metabolism in aging and disease.

Authors:  Xiaogang Chu; Raghavan Pillai Raju
Journal:  Metabolism       Date:  2021-10-28       Impact factor: 8.694

2.  Synthesis of Mixed Dinucleotides by Mechanochemistry.

Authors:  Faisal Hayat; Mikhail V Makarov; Luxene Belfleur; Marie E Migaud
Journal:  Molecules       Date:  2022-05-18       Impact factor: 4.927

Review 3.  Metabolic Therapy of Heart Failure: Is There a Future for B Vitamins?

Authors:  Jérôme Piquereau; Solène E Boitard; Renée Ventura-Clapier; Mathias Mericskay
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

Review 4.  NAD+ in COVID-19 and viral infections.

Authors:  Minyan Zheng; Michael B Schultz; David A Sinclair
Journal:  Trends Immunol       Date:  2022-02-11       Impact factor: 16.687

5.  Dihydronicotinamide Riboside Is a Potent NAD+ Precursor Promoting a Pro-Inflammatory Phenotype in Macrophages.

Authors:  Claudia C S Chini; Thais R Peclat; Lilian S Gomez; Julianna D Zeidler; Gina M Warner; Sonu Kashyap; Delaram Z Mazdeh; Faisal Hayat; Marie E Migaud; Aneel Paulus; Asher A Chanan-Khan; Eduardo N Chini
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 8.786

Review 6.  The role of NAD and NAD precursors on longevity and lifespan modulation in the budding yeast, Saccharomyces cerevisiae.

Authors:  Chuks Kenneth Odoh; Xiaojia Guo; James T Arnone; Xueying Wang; Zongbao K Zhao
Journal:  Biogerontology       Date:  2022-03-09       Impact factor: 4.284

7.  Treatment of SARS-CoV-2-induced pneumonia with NAD+ and NMN in two mouse models.

Authors:  Yisheng Jiang; Yongqiang Deng; Huanhuan Pang; Tiantian Ma; Qing Ye; Qi Chen; Haiyang Chen; Zeping Hu; Cheng-Feng Qin; Zhiheng Xu
Journal:  Cell Discov       Date:  2022-04-29       Impact factor: 38.079

Review 8.  Mitochondrial transport and metabolism of the vitamin B-derived cofactors thiamine pyrophosphate, coenzyme A, FAD and NAD+ , and related diseases: A review.

Authors:  Ferdinando Palmieri; Magnus Monné; Giuseppe Fiermonte; Luigi Palmieri
Journal:  IUBMB Life       Date:  2022-03-18       Impact factor: 4.709

Review 9.  NAD+ Precursors: A Questionable Redundancy.

Authors:  Carles Canto
Journal:  Metabolites       Date:  2022-07-09

Review 10.  Balancing NAD+ deficits with nicotinamide riboside: therapeutic possibilities and limitations.

Authors:  Angelique Cercillieux; Eleonora Ciarlo; Carles Canto
Journal:  Cell Mol Life Sci       Date:  2022-08-02       Impact factor: 9.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.